Logo image of YCBD

CBDMD INC (YCBD) Stock Fundamental Analysis

USA - NYSE Arca - NYSEARCA:YCBD - US12482W4087 - Common Stock

1.07 USD
-0.01 (-0.93%)
Last: 1/9/2026, 8:04:00 PM
1.05 USD
-0.02 (-1.87%)
After Hours: 1/9/2026, 8:04:00 PM
Fundamental Rating

1

YCBD gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 191 industry peers in the Pharmaceuticals industry. The financial health of YCBD is average, but there are quite some concerns on its profitability. YCBD does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

YCBD had negative earnings in the past year.
In the past year YCBD has reported a negative cash flow from operations.
In the past 5 years YCBD always reported negative net income.
YCBD had a negative operating cash flow in each of the past 5 years.
YCBD Yearly Net Income VS EBIT VS OCF VS FCFYCBD Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M

1.2 Ratios

YCBD has a Return On Assets of -49.02%. This is in the lower half of the industry: YCBD underperforms 60.21% of its industry peers.
The Return On Equity of YCBD (-79.38%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -49.02%
ROE -79.38%
ROIC N/A
ROA(3y)-140.25%
ROA(5y)-86.1%
ROE(3y)-308.88%
ROE(5y)-187.27%
ROIC(3y)N/A
ROIC(5y)N/A
YCBD Yearly ROA, ROE, ROICYCBD Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -200 -400 -600 -800

1.3 Margins

With a decent Gross Margin value of 61.20%, YCBD is doing good in the industry, outperforming 71.73% of the companies in the same industry.
YCBD's Gross Margin has been stable in the last couple of years.
YCBD does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 61.2%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.98%
GM growth 5Y0.07%
YCBD Yearly Profit, Operating, Gross MarginsYCBD Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100 -200 -300

More info and screens

4

2. Health

2.1 Basic Checks

YCBD does not have a ROIC to compare to the WACC, probably because it is not profitable.
YCBD has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
YCBD Yearly Shares OutstandingYCBD Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 100K 200K 300K 400K
YCBD Yearly Total Debt VS Total AssetsYCBD Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -22.24, we must say that YCBD is in the distress zone and has some risk of bankruptcy.
YCBD has a worse Altman-Z score (-22.24) than 85.34% of its industry peers.
There is no outstanding debt for YCBD. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -22.24
ROIC/WACCN/A
WACC9.38%
YCBD Yearly LT Debt VS Equity VS FCFYCBD Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M 40M 60M 80M 100M

2.3 Liquidity

YCBD has a Current Ratio of 1.56. This is a normal value and indicates that YCBD is financially healthy and should not expect problems in meeting its short term obligations.
YCBD has a worse Current ratio (1.56) than 71.20% of its industry peers.
YCBD has a Quick Ratio of 1.56. This is a bad value and indicates that YCBD is not financially healthy enough and could expect problems in meeting its short term obligations.
The Quick ratio of YCBD (0.78) is worse than 83.77% of its industry peers.
Industry RankSector Rank
Current Ratio 1.56
Quick Ratio 0.78
YCBD Yearly Current Assets VS Current LiabilitesYCBD Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 70.81% over the past year.
EPS 1Y (TTM)70.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.13%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.59%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y94.95%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year4.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
YCBD Yearly Revenue VS EstimatesYCBD Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 10M 20M 30M 40M
YCBD Yearly EPS VS EstimatesYCBD Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2023 2024 2025 2026 0 -500 -1K -1.5K

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

YCBD reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for YCBD. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
YCBD Price Earnings VS Forward Price EarningsYCBD Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
YCBD Per share dataYCBD EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

YCBD does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

CBDMD INC

NYSEARCA:YCBD (1/9/2026, 8:04:00 PM)

After market: 1.05 -0.02 (-1.87%)

1.07

-0.01 (-0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)12-19 2025-12-19/amc
Earnings (Next)02-11 2026-02-11
Inst Owners4.63%
Inst Owner Change0%
Ins Owners6.34%
Ins Owner Change30.68%
Market Cap9.53M
Revenue(TTM)N/A
Net Income(TTM)-4.85M
Analysts82.86
Price Target2.04 (90.65%)
Short Float %56.48%
Short Ratio0.3
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-472.92%
Min EPS beat(2)-929.41%
Max EPS beat(2)-16.42%
EPS beat(4)2
Avg EPS beat(4)-215.74%
Min EPS beat(4)-929.41%
Max EPS beat(4)41.71%
EPS beat(8)4
Avg EPS beat(8)-101.11%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.14%
Min Revenue beat(2)-14.83%
Max Revenue beat(2)-9.45%
Revenue beat(4)0
Avg Revenue beat(4)-8.67%
Min Revenue beat(4)-14.83%
Max Revenue beat(4)-3.36%
Revenue beat(8)1
Avg Revenue beat(8)-8.77%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.5
P/FCF N/A
P/OCF N/A
P/B 1.56
P/tB 2.51
EV/EBITDA N/A
EPS(TTM)-4.04
EYN/A
EPS(NY)-0.2
Fwd EYN/A
FCF(TTM)-0.15
FCFYN/A
OCF(TTM)-0.12
OCFYN/A
SpS2.14
BVpS0.69
TBVpS0.43
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.02%
ROE -79.38%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 61.2%
FCFM N/A
ROA(3y)-140.25%
ROA(5y)-86.1%
ROE(3y)-308.88%
ROE(5y)-187.27%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-2.98%
GM growth 5Y0.07%
F-Score5
Asset Turnover1.92
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 25.3%
Cap/Sales 1.53%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.56
Quick Ratio 0.78
Altman-Z -22.24
F-Score5
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)26.48%
Cap/Depr(5y)59.22%
Cap/Sales(3y)1.56%
Cap/Sales(5y)1.72%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)70.81%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.13%
EPS Next Y94.95%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%3.59%
Revenue Next Year4.95%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y64.11%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y77.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y82.51%
OCF growth 3YN/A
OCF growth 5YN/A

CBDMD INC / YCBD FAQ

What is the ChartMill fundamental rating of CBDMD INC (YCBD) stock?

ChartMill assigns a fundamental rating of 1 / 10 to YCBD.


What is the valuation status of CBDMD INC (YCBD) stock?

ChartMill assigns a valuation rating of 0 / 10 to CBDMD INC (YCBD). This can be considered as Overvalued.


How profitable is CBDMD INC (YCBD) stock?

CBDMD INC (YCBD) has a profitability rating of 1 / 10.


How sustainable is the dividend of CBDMD INC (YCBD) stock?

The dividend rating of CBDMD INC (YCBD) is 0 / 10 and the dividend payout ratio is 0%.